Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin, attention bias modification training, and neurofeedback for social anxiety symptoms
NL-OMON57669Recruiting
- Sponsor
- Maastricht University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of psilocybin in Social Anxiety Disorder (SAD) (6 arms), sponsored by Maastricht University. Primary endpoint: Change in negative attention biases. Started Aug 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NL-OMON57669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57669.